STRIDE-based immunotherapy plus TACE shows promising outcomes in embolisation-eligible HCC

Reduced dosing frequency of immune checkpoint inhibitors raises survival concerns in advanced cancer

Adding nivolumab to perioperative chemo shows no significant benefit in muscle invasive bladder cancer

Camupepimut shows early disease free survival signal in resected KRAS mutated pancreatic cancer

Zoldonrasib plus daraxonrasib targets KRAS G12D in metastatic pancreatic cancer with promising early results

P-32 microparticle brachytherapy plus FOLFIRINOX shows promising local control in unresectable pancreatic cancer

Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS

ctDNA MRD status predicts survival and adjuvant chemo benefit in resected colorectal liver metastas

STRIDE ± lenvatinib plus TACE improves outcomes in unresectable early-to-intermediate HCC

ASCO 2026: Highlights and analysis

Olaparib plus pembrolizumab improves response but not PFS in BRCA-mutant pancreatic cancer

Daraxonrasib nearly doubles survival in previously treated metastatic pancreatic cancer